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SuMMARy
Glivec is a drug used in the treatment of chronic myeloid leukaemia (CML) and gastro-
intestinal stromal tumours (GISI). It is an expensive drug which would be out of reach 
for most patients in Kenya. Norvatis Pharmaceutical together with Axios International 
a healthcare management company and Max Foundation have made it possible for 
patients in developing countries to get access to the drug at no cost. Patients meet the 
cost of the confirmatory test and are recruited into the programme to receive the drug 
at no cost. A total of 201 patients are in the programme in Nairobi, mainly drawn from 
Kenyatta National Hospital the major referral hospital in Kenya. The age range is nine 
years to 75 years with a mean age of 39.5 years. Males make up 56.5% while females are 
43.5%. CML are 173 (86%) while GIST patients are 28 (13.9%). Most of the CML cases 
are referred in the chronic stable phase (87.8%) and 85.7% have been on hydroxyurea 
as the initial treatment. Compliance rates are approximately  80%. 
INTROduCTION
Glivec (imatinib) is a drug used in treatment of 
patients diagnosed with philadelphia chromosome-
positive chronic myeloid leukaemia (ph+ cml) 
or gastrointestinal stromal tumours (GisT). it was 
approved for use in 2002 and is marketed by the 
pharmaceutical company norvatis. Due to the 
restrictive cost of the drug very few patients in 
developing countries can get access to use of this drug. 
(The approximate cost per month for one patient is 
Kshs 400,000 or Us $ 5334). Glivec international 
patient assistance programme (Gipap) helps patients 
who are not insured, not reimbursed and who cannot 
pay for treatment privately and are in developing 
countries with minimal resource capabilities to access 
the drug. Glivec global patient access programmes 
include a range of flexible models including shared 
donation (charities, government bodies and other 
payers partner with norvatis to provide glivec free 
to patients), full pay (norvatis pays fully for glivec), 
or co-pay (norvatis and the patient share the cost 
of glivec) models.  national and local partnerships 
are used to implement these Glivec patient access 
programmes with a goal to provide the best cancer 
care possible for the greatest number of patients.
 over 34,500 patients in 80 countries who would 
otherwise, not have been able to afford treatment 
have benefited from the programme.  
  norvatis partners with axios international a 
consulting company founded in 1997 that specialises 
in strategic advice and technical assistance to improve 
healthcare delivery services in low and middle 
income countries. axios’ origins go back to the early 
years of the battle for hiv treatment where people 
felt that developing countries were ‘too poor and 
too un-educated’ to be able to use antiretrovirals 
(arvs). most opinion leaders maintained that patients 
in developing countries would not be compliant with 
arvs treatment and that giving these patients access 
to arvs would be risky, irresponsible and create 
arv resistance.  axios pioneered arv programmes 
in cote d’ ivoire, vietnam, chile and Uganda that 
proved that arv treatment could be done safely and 
effectively in developing countries and it opened the 
door for the subsequent price reductions and arv 
initiatives for developing countries.
  The other norvatis partner is the max Foundation 
a US-based non-profit cancer organization with 
international focus. The max Foundation honours life 
of maximiliano (max) rivarola who was diagnosed 
with chronic myeloid leukaemia (cml) at the age of 
14 years and lived with outstanding courage until 
17 years of age. The Foundation’s focus has been to 
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help patients diagnosed with blood and rare cancers 
by facilitating access to treatment and providing care 
and support for those who have limited access to 
resources.
CASE STudy
The Gipap started in Kenya in 2002 in two centres; the 
nairobi hospital and the aga Khan University hospital. 
The operational team involved in Gipap includes 
five doctors, two pharmacists, other two health care 
workers. Three consultants volunteer their services, 
while the nairobi hospital offers the administrative 
frame work by providing a secretary, the pharmacists, 
a medical officer and also space to run the clinic every 
two weeks; at no charge to the patient. 
  majority of the patients seen are drawn from 
Kenyatta national hospital where they are usually 
referred from peripheral centres for management of 
their cancers. The preliminary diagnosis often has 
been made at the primary health care facilities ; cml 
patients will have  a diagnostic bone marrow aspirate 
while GisT patients a biopsy  histopathology report. 
  The entry point into the programme is for the 
cml patients to get a philadelphia chromosome test 
(cytogenetic defect: t (q; 22) (q34; q11)) or abl/ bcr 
positive Fish test. The patient meets the cost of this test 
which is approximately kshs 18,000 or Us $ 240.  The 
GIST patients are required to do a confirmatory CD 
117 immunophenotyping or platelet derived growth 
factor receptor (pDGFr), TK mutation testing which 
costs approximately kshs 6,000kshs or Us $ 80. For 
some patients this is impossible. many of the patients 
sell off some property or call for contributions from 
their communities or extended families to carry out 
the test due to the promise of more effective free life 
-long better treatment thereafter.
  The application is done under one of the 
three Gipap consultants and data on  patients’ 
epidemiological details, stage of disease and history 
of previous treatments is input and emailed to the 
axios international coordinator.  a response takes 
24 to 48 hours and  patients get an individual Gipap 
number.
  all patients are commenced on glivec 400mg once 
a day and an initial prescription for a month is given 
with a clinic date for review. at this outpatient visit a 
clinical assessment for response and toxicities is done 
and blood test results are reviewed. Dose adjustments 
are made accordingly. patients with co-morbidities 
are advised to adhere to their other specialist clinics. 
When patients require other specialist reviews they 
are referred to their primary referral facilities or to 
Kenyatta national hospital. 
  on a regular basis patients are reassessed for re-
approval to continue on glivec. The current dosing, 
toxicities and other outcomes are updated. 
The Nairobi GIPAP:  The programme started in nairobi 
in 2002 and by november 2009,  201 patients were 
receiving glivec free of charge in the programme. 
cml patients make up 173 (86%) males and 28 (13.9%) 
females of the patients on treatment. 
  male patients are 113 (56.5%) and female patients 
were 88 (40.4%). The age distribution is nine years 
to 75 years.  most of the patient come from central 
province with 81% being Kikuyus, luo 17(9.1%) 
and luhya 11(5.9%). This is thought to be due to 
catchment area of Kenyatta national hospital which 
is the main source of patients.  For the cml patients 
87.8% of patients are referred at the chronic stable 
phase. hydroxyurea is the drug commonly previously 
prescribed in up to 85.7% of cml cases.  compliance 
rates are well over 80% mainly due to the motivation of 
improvement noted by the patient. The patients came 
up with a patient support group which is involved 
in counselling and creating awareness about the 
two conditions. They aim to increase referrals to the 
clinic so that more deserving patients benefit from 
the treatment
Challenges of the programme: The programme offers 
access to glivec for a very small proportion of patients 
with cml and GisT in Kenya. This is mainly due to 
lack of awareness by clinicians and the public even in 
nairobi. The tests required as an entry point into the 
programme are not available in Kenya and the blood 
samples are sent abroad which is the main reason it 
is unaffordable to many patients. some patients lack 
resources to travel for clinic appointments or to pick 
up their drugs and they are also unable to carry out 
the blood tests for comprehensive follow-up. some 
patients have developed resistance to glivec and 
the tests required for application to receive second 
line treatment with nilotinib are quite restrictive 
in cost. This process also takes a long time. The 
biggest worry of course is the sustainability of the 
“full pay” model where norvatis supports the total 
cost of the drug.
CONCLuSION
as we celebrate the achievements of professor 
edward George Kasili, there is the  realisation of the 
long journey ahead. The Glivec international patient 
assistance programme has saved the lives of many 
patients. as we look into ways of increasing awareness 
and referrals so that more patients may benefit, we 
should also find ways of supporting the investigations 
needed before treatment. other partners including 
government may be needed to sustain treatment to 
bigger numbers of patients. arv success story gives 
us hope. cancer management is costly sometimes 
without a promise of longevity, but this may be the 
path to follow other malignancies as well. 
